AMGN Amgen
Data as of close
Dow Jones CompaniesNasdaq 100 CompaniesS&P 500 Companies
Healthcare · Biological Products, (No Diagnostic Substances)
Amgen (AMGN) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $251.7 billion. Shares last traded at $465.48, near their 52-week high. Over the past year the stock is up 59.4%. AMGN trades at a price-to-earnings ratio of 28.78, above the Biological Products, (No Diagnostic Substances) median of 20.95. Net profit margin is 23.0%, above the peer median of -1.6%. Revenue grew 10.0% year over year. The shares yield 2.1% in dividends.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
AMGN Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2025-12-31 | $5.12B | $9.45 | 66% |
| 2024-12-31 | $4.83B | $8.93 | 118% |
| 2023-12-31 | $4.56B | $8.47 | 68% |
| 2022-12-31 | $4.20B | $7.76 | 64% |
| 2021-12-31 | $4.01B | $7.00 | 68% |
| 2020-12-31 | $3.75B | $6.36 | 52% |
| 2019-12-31 | $3.51B | $5.76 | 45% |
| 2018-12-31 | $3.51B | $5.27 | 42% |
| 2017-12-31 | $3.37B | $4.58 | 170% |
| 2016-12-31 | $3.00B | $3.98 | 39% |
| 2015-12-31 | $2.40B | $3.13 | 35% |
| 2014-12-31 | $1.85B | $2.40 | 36% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $4.37 | 2026-08-05 |
| Q1 2026 | $3.34 | 2026-05-01 |
| Q4 2025 (derived) | $2.45 | 2026-02-13 |
| FY 2025 | $14.23 | 2026-02-13 |
| Q3 2025 | $5.93 | 2025-11-05 |
| Q2 2025 | $2.65 | 2025-08-06 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
Biological Products, (No Diagnostic Substances) peers
AMGN vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Data as of close
| AMGN | Amgen | $251.7B | 28.78 | 6.61 | 23.0% | -0.13% |
| GILD | Gilead Sciences | $211.3B | — | 6.82 | -12.5% | -0.23% |
| MRNA | Moderna | $88.2B | — | — | — | -0.12% |
| RVMD | Revolution Medicines, Inc. | $40.4B | — | — | — | -1.58% |
| BIIB | Biogen | $36.8B | 105.92 | 3.57 | 3.4% | -1.83% |
| EXEL | Exelixis, Inc. | $17.1B | 19.32 | 6.85 | 35.5% | +1.02% |
| NBIX | Neurocrine Biosciences Inc | $14.7B | 20.95 | 3.98 | 19.0% | -0.52% |
| HALO | Halozyme Therapeutics, Inc. | $14.6B | 35.38 | 8.80 | 24.9% | -1.50% |
| TECH | Bio-Techne | $11.4B | 62.76 | 9.39 | 15.0% | -0.03% |
| RGEN | Repligen Corp | $11.1B | — | 13.73 | -1.5% | -2.17% |
| QGEN | Qiagen N.V. | $10.9B | 25.70 | 5.22 | 20.3% | +0.33% |
| KYMR | Kymera Therapeutics, Inc. | $10.9B | — | — | — | +0.68% |
| PCVX | Vaxcyte, Inc. | $9.0B | — | — | — | -2.26% |
| KRYS | Krystal Biotech, Inc. | $8.8B | 38.95 | 18.66 | 47.9% | -10.76% |
🇨🇦 Amgen also trades on Cboe Canada as a CAD-hedged Canadian Depositary Receipt (CDR) under AMGN. A CDR represents the same underlying AMGN shares in Canadian dollars with the currency exposure hedged; this page tracks the US-listed shares.
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.